CRISPR Therapeutics (CRSP) Fundamentals 2026 — Revenue Analysis | SniperIQ
CRISPR Therapeutics (CRSP) is a CH-listed Healthcare company in Biotechnology with a market capitalization of $4.5B, trading at $47.04 on the NASDAQ. This SniperIQ fundamentals page covers CRISPR Therapeutics's valuation, profitability (net margin -13856.5%), revenue ($4M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is CRISPR Therapeutics's market cap?
CRISPR Therapeutics (CRSP) has a market capitalization of approximately $4.5B, trading at $47.04 on the NASDAQ. Market cap moves with the live share price.
What is CRISPR Therapeutics's P/E ratio?
CRISPR Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is CRISPR Therapeutics?
CRISPR Therapeutics runs a net profit margin of -13856.5%, a gross margin of -5360.9%, and an operating margin of -13408.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does CRISPR Therapeutics generate?
CRISPR Therapeutics reported revenue of $4M for fiscal year 2025, with net income of -$582M and earnings per share (EPS) of -6.47. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does CRISPR Therapeutics pay a dividend?
CRISPR Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is CRISPR Therapeutics financially healthy?
CRISPR Therapeutics carries a debt-to-equity ratio of 0.43x and a current ratio of 17.96x, with a market beta of 1.70. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is CRISPR Therapeutics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CRISPR Therapeutics (CRSP) the key facts are: market cap $4.5B, revenue $4M, 52-week range 44.12-78.48. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track CRISPR Therapeutics's full fundamentals live
Get CRISPR Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.